Structurally distinct hybrid polymer/lipid nanoconstructs harboring a type-I ribotoxin as cellular imaging and glioblastoma-directed therapeutic vectors

M Sheikh Mohamed; Srivani Veeranarayanan; Ankur Baliyan; Aby Cheruvathoor Poulose; Yutaka Nagaoka; Hiroaki Minegishi; Seiki Iwai; Yasuhiro Shimane; Yasuhiko Yoshida; Toru Maekawa; D Sakthi Kumar

doi:10.1002/mabi.201400248

Structurally distinct hybrid polymer/lipid nanoconstructs harboring a type-I ribotoxin as cellular imaging and glioblastoma-directed therapeutic vectors

Macromol Biosci. 2014 Dec;14(12):1696-711. doi: 10.1002/mabi.201400248. Epub 2014 Sep 2.

Authors

M Sheikh Mohamed¹, Srivani Veeranarayanan, Ankur Baliyan, Aby Cheruvathoor Poulose, Yutaka Nagaoka, Hiroaki Minegishi, Seiki Iwai, Yasuhiro Shimane, Yasuhiko Yoshida, Toru Maekawa, D Sakthi Kumar

Affiliation

¹ Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science Toyo University, Kawagoe, Saitama, 350-8585, Japan.

PMID: 25181322
DOI: 10.1002/mabi.201400248

Abstract

A nanoformulation composed of a ribosome inactivating protein-curcin and a hybrid solid lipid nanovector has been devised against glioblastoma. The structurally distinct nanoparticles were highly compatible to human endothelial and neuronal cells. A sturdy drug release from the particles, recorded upto 72 h, was reflected in the time-dependent toxicity. Folate-targeted nanoparticles were specifically internalized by glioma, imparting superior toxicity and curbed an aggressively proliferating in vitro 3D cancer mass in addition to suppressing the anti-apoptotic survivin and cell matrix protein vinculin. Combined with the imaging potential of the encapsulated dye, the nanovector emanates as a multifunctional anti-cancer system.

Keywords: brain cancer; curcin; folate targeting; ribosome inactivating protein; solid lipid nanoparticles.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis / drug effects
Brain Neoplasms* / drug therapy
Brain Neoplasms* / metabolism
Brain Neoplasms* / pathology
Cell Line, Tumor
Delayed-Action Preparations / chemistry
Delayed-Action Preparations / pharmacokinetics
Delayed-Action Preparations / pharmacology
Drug Screening Assays, Antitumor
Endothelial Cells / metabolism
Endothelial Cells / pathology
Glioblastoma* / drug therapy
Glioblastoma* / metabolism
Glioblastoma* / pathology
Humans
Inhibitor of Apoptosis Proteins / metabolism
Lipids* / chemistry
Lipids* / pharmacokinetics
Lipids* / pharmacology
Molecular Imaging*
Nanostructures / chemistry*
Neoplasm Proteins / metabolism
Neurons / metabolism
Neurons / pathology
Ribosome Inactivating Proteins, Type 1* / chemistry
Ribosome Inactivating Proteins, Type 1* / pharmacokinetics
Ribosome Inactivating Proteins, Type 1* / pharmacology
Survivin
Vinculin / metabolism

Substances

BIRC5 protein, human
Delayed-Action Preparations
Inhibitor of Apoptosis Proteins
Lipids
Neoplasm Proteins
Ribosome Inactivating Proteins, Type 1
Survivin
VCL protein, human
curcin protein, Jatropha curcas
Vinculin